Abstract: Improved prime editing systems having pegRNA with reduced auto-inhibition, and methods of their use, are described.

Abstract: The present disclosure provides antisense compounds, methods, and compositions for silencing ADAM33 mRNA. The present disclosure provides antisense compounds, methods, and compositions for the treatment, prevention, or amelioration of diseases, disorders, and conditions associated with ADAM33 in a subject in need thereof. Also contemplated are antisense compounds and methods for the preparation of a medicament for the treatment, prevention, or amelioration of a disease, disorder, or condition associated with ADAM33.

Abstract: The present disclosure provides antisense compounds, methods, and compositions for increasing FXN gene expression. The present disclosure provides antisense compounds, methods, and compositions for the treatment, prevention, or amelioration of diseases, disorders, and conditions associated with FXN in a subject in need thereof. Also contemplated are antisense compounds and methods for the preparation of a medicament for the treatment, prevention, or amelioration of a disease, disorder, or condition associated with FXN.

Abstract: This disclosure relates to novel SARS-CoV-2 targeting sequences. Novel SARS-CoV-2 targeting oligonucleotides for the treatment of SARS-CoV-2 infection are also provided.

Abstract: Provided herein, in various embodiments, are methods of treating a fragile X-associated disorder (e.g., fragile X syndrome), comprising administering to a subject in need thereof, a therapeutically effective amount of an agent that decreases expression of an aberrant fragile X messenger ribonucleoprotein 1 (FMR1) gene product (e.g., FMR1-217). Also provided herein, in various embodiments, are compositions (e.g., polynucleotides such as antisense oligonucleotides or pharmaceutical compositions) for decreasing expression of an aberrant FMR1 gene product.

Abstract: This disclosure relates to novel SARS-CoV-2 targeting sequences. Novel SARS-CoV-2 targeting oligonucleotides for the treatment of SARS-CoV-2 infection are also provided.

Abstract: This disclosure relates to compounds (“siRNASO”) comprising a double stranded RNA (dsRNA) attached to antisense oligonucleotides (ASO) and heteroduplex oligonucleotides (HDO). Also provided are methods of inhibiting gene expression with the same.

Abstract: In a method for applying deterministic logic to select resources for resource genomes in a genetic algorithm, a logic engine identifies resources associated with an objective and an overall task population to be completed by one or more of the identified resources. The logic engine then selects a deterministic logical framework from one or more deterministic logical frameworks based on the objective. Following the selection of a deterministic logical framework, the logic engine selects one or more resources from the one or more identified resources based on the selected deterministic logical framework. The logic engine compiles the one or more selected resources into a resource genome, assigns one or more tasks from the task population to the one or more selected resources, and sends instructions to the one or more selected resources to execute the one or more tasks. The logic engine determines a value score for the resource genome.

Abstract: The present disclosure provides antisense compounds, methods, and compositions for silencing ADAM33 mRNA. The present disclosure provides antisense compounds, methods, and compositions for the treatment, prevention, or amelioration of diseases, disorders, and conditions associated with ADAM33 in a subject in need thereof. Also contemplated are antisense compounds and methods for the preparation of a medicament for the treatment, prevention, or amelioration of a disease, disorder, or condition associated with ADAM33.

Abstract: This disclosure relates to novel SARS-CoV-2 targeting sequences. Novel SARS-CoV-2 targeting oligonucleotides for the treatment of SARS-CoV-2 infection are also provided.

Abstract: The present disclosure provides antisense compounds, methods, and compositions for silencing ADAM33 mRNA. The present disclosure provides antisense compounds, methods, and compositions for the treatment, prevention, or amelioration of diseases, disorders, and conditions associated with ADAM33 in a subject in need thereof. Also contemplated are antisense compounds and methods for the preparation of a medicament for the treatment, prevention, or amelioration of a disease, disorder, or condition associated with ADAM33.

Abstract: The present disclosure provides antisense compounds, methods, and compositions for increasing FXN gene expression. The present disclosure provides antisense compounds, methods, and compositions for the treatment, prevention, or amelioration of diseases, disorders, and conditions associated with FXN in a subject in need thereof. Also contemplated are antisense compounds and methods for the preparation of a medicament for the treatment, prevention, or amelioration of a disease, disorder, or condition associated with FXN.

Abstract: In a method for applying deterministic logic to select resources for resource genomes in a genetic algorithm, a logic engine identifies resources associated with an objective and an overall task population to be completed by one or more of the identified resources. The logic engine then selects a deterministic logical framework from one or more deterministic logical frameworks based on the objective. Following the selection of a deterministic logical framework, the logic engine selects one or more resources from the one or more identified resources based on the selected deterministic logical framework. The logic engine compiles the one or more selected resources into a resource genome, assigns one or more tasks from the task population to the one or more selected resources, and sends instructions to the one or more selected resources to execute the one or more tasks. The logic engine determines a value score for the resource genome.

Abstract: In a method for applying deterministic logic to select resources for resource genomes in a genetic algorithm, a logic engine identifies resources associated with an objective and an overall task population to be completed by one or more of the identified resources. The logic engine then selects a deterministic logical framework from one or more deterministic logical frameworks based on the objective. Following the selection of a deterministic logical framework, the logic engine selects one or more resources from the one or more identified resources based on the selected deterministic logical framework. The logic engine compiles the one or more selected resources into a resource genome, assigns one or more tasks from the task population to the one or more selected resources, and sends instructions to the one or more selected resources to execute the one or more tasks. The logic engine determines a value score for the resource genome.

Abstract: In a method for applying deterministic logic to select resources for resource genomes in a genetic algorithm, a logic engine identifies resources associated with an objective and an overall task population to be completed by one or more of the identified resources. The logic engine then selects a deterministic logical framework from one or more deterministic logical frameworks based on the objective. Following the selection of a deterministic logical framework, the logic engine selects one or more resources from the one or more identified resources based on the selected deterministic logical framework. The logic engine compiles the one or more selected resources into a resource genome, assigns one or more tasks from the task population to the one or more selected resources, and sends instructions to the one or more selected resources to execute the one or more tasks. The logic engine determines a value score for the resource genome.

Abstract: The present disclosure provides antisense compounds, methods, and compositions for silencing ADAM33 mRNA. The present disclosure provides antisense compounds, methods, and compositions for the treatment, prevention, or amelioration of diseases, disorders, and conditions associated with ADAM33 in a subject in need thereof. Also contemplated are antisense compounds and methods for the preparation of a medicament for the treatment, prevention, or amelioration of a disease, disorder, or condition associated with ADAM33.

Abstract: A generic interface for a module, method of providing a generic interface, and a module controller system providing a register slave having a generic interface are described. The interface includes an addressable interface, a control interface, and a module interface configured to interact with two or more module configurations. The interface has multiple operating modes at least one of which includes a monitor mode. The method includes receiving an address from a register master identifying the module address to be monitored, reading the received module address content from the module, and transmitting the read content to the monitor port. The system includes a register master, a register slave connected with the register master and adapted to connect with the module, and a monitor port connected with the register slave to receive the monitored module address contents.

Abstract: A method for testing a network device having modules for receiving and sending data packets in a network includes generating in the network device at least one internal data structure associated with a data packet received by the network device from the network. A predefined action on the network device is then preformed responsive to the internal data structure indicating that the data packet satisfies a predefined condition.

Abstract: A retinal camera is used to examine an eye, the camera including a light source having first and second sources emitting first and second wavelength bands. The first and second light sources are arranged to alternately produce light onto the retina such that the absorptivity of light of the first wavelength band by oxygenated blood is greater than the absorptivity of light of the second wavelength band, and the absorptivity of light of the first wavelength band by the oxygenated blood is less than absorptivity of light of the second wavelength band. Light is selectively focused from the first and second sources by an optical arrangement and imaging devices produce respective images of a portion of the retina illuminated with the respective wavelength bands. The images obtained by the imaging device are processed by the imaging device and processor to determine a retinal metabolic image based on haemoglobin oxygenation. In an embodiment of the invention light is scanned across the retina.

Abstract: Systems, methods, and devices are disclosed that provide packet protection for header modification. One method includes receiving a packet to a computing device. The method includes apply error checking techniques independently to different portions of the packet.